Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL22608563

O=C(O)C(F)(F)F.O=C(O)c1[nH]nnc1C1CCc2ccccc2C1

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 6/20 0.37
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PRKDC P78527 1/20 0.34
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
AKR1C3 P42330 1/20 0.33
KDM1A O60341 1/20 0.33
DAPK3 O43293 1/20 0.32
JAK2 O60674 1/20 0.32
CSF1R P07333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL29490703 1.00 HCAR2 (0.37) HCAR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL22816435 0.93 HCAR2 (0.39) HCAR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL22608564 0.83 PIK3CD (0.32) HCAR2PIK3CDPIK3CAPIK3CBPIK3CG
Trifluoroacetic Acid SCHEMBL22608164 0.79 HAO1 (0.39) HAO1
Trifluoroacetic Acid SCHEMBL29490726 0.79 HAO1 (0.39) HAO1
Trifluoroacetic Acid SCHEMBL29514846 0.71 GRIN2D (0.42) KDM4EALDH1A1LMNAMAPTHPGD
Trifluoroacetic Acid SCHEMBL22608799 0.71 GRIN2D (0.42) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL29514738 0.70 HAO1 (0.43) HAO1
SCHEMBL22816396 0.70 HAO1 (0.43) HAO1
Trifluoroacetic Acid SCHEMBL22608506 0.67 NISCH (0.37) KDM4EALDH1A1KDM1AHAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117126152-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 CN disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
EP-3986863-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2022-04-27 EP disclosed
CN-114258390-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2022-03-29 CN disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
EP-3732167-A2 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2020-11-04 EP disclosed
CN-111788187-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2020-10-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HCAR2 1540/4885PIK3CD 4205/4885PIK3CA 3488/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HCAR2 1507/4885PIK3CD 4168/4885PIK3CA 3337/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HCAR2 1540/4885PIK3CD 4205/4885PIK3CA 3488/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HCAR2 1540/4885PIK3CD 4205/4885PIK3CA 3488/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HCAR2 1540/4885PIK3CD 4205/4885PIK3CA 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.